8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 27, 2026·SEC
Kodiak Sciences Inc.(KOD)Earnings, Financials & Key Ratios
KOD•NASDAQ
Price updated Jun 19, 2026
AboutKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Show more
- Revenue$0
- EBITDA-$234M-46.4%
- Net Income-$230M-30.5%
- EPS (Diluted)-4.32-29.0%
- ROE-149.49%-76.5%
KOD Key Insights
Kodiak Sciences Inc. (KOD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 91 (top 9%)
✗Weaknesses
- ✗Profits declining 11.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Expensive at 12.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KOD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KOD Price & Volume
Kodiak Sciences Inc. (KOD) stock price & volume — 10-year historical chart
Loading chart...
KOD Growth Metrics
Kodiak Sciences Inc. (KOD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-14.88%
Return on Capital
10 Years-192.24%
5 Years-50.85%
3 Years-59.61%
Last Year-76.1%
KOD Recent Earnings
Kodiak Sciences Inc. (KOD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.94-1.1%
$0.93
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$1.04-2.0%
$1.02
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.16-8.4%
$1.07
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.03-2.0%
$1.01
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.94vs $0.93-1.1% | — |
| Q2 2026 | Mar 31, 2026 | $1.04vs $1.02-2.0% | — |
| Q4 2025 | Nov 13, 2025 | $1.16vs $1.07-8.4% | — |
| Q3 2025 | Aug 13, 2025 | $1.03vs $1.01-2.0% | — |
Based on last 12 quarters of dataView full earnings history →
KOD Peer Comparison
Kodiak Sciences Inc. (KOD) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADVM | 96.26M | 4.36 | -0.66 | -72.22% | -189.84% | 1.30 | ||
 OCUL | 2.06B | 9.43 | -6.64 | -18.67% | -5.58% | -64.55% | 0.12 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 RGNX | 403.24M | 7.80 | -2.07 | 104.54% | -330.23% | -232.5% | 2.54 | |
 GMAB | 15.51B | 25.27 | 16.41 | -82.7% | 29.58% | 20.56% | 0.93 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare KOD vs Peers
Kodiak Sciences Inc. (KOD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KOD Income Statement
Kodiak Sciences Inc. (KOD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 549K | 490K | 911K | 4.21M | 8.71M | 11M | 25.95M | 26.71M | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -549K▲ 0% | -490K▲ 10.7% | -911K▼ 85.9% | -4.21M▼ 361.9% | -8.71M▼ 107.0% | -11M▼ 26.3% | -25.95M▼ 135.9% | -26.71M▼ 2.9% | 0▲ 100.0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -113.62% | 10.75% | -85.92% | -361.91% | -107.01% | -26.29% | -135.86% | -2.93% | 100% | - |
Operating Expenses | 25.52M | 26.37M | 48.28M | 131.8M | 258.34M | 330.38M | 251.37M | 160.14M | 234.39M | 235.09M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 3.5M | 7.58M | 10.77M | 24.41M | 41M | 62.79M | 71.02M | 34.05M | 52.02M | 47.82M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 22.02M | 18.79M | 37.51M | 107.39M | 217.34M | 267.59M | 206.3M | 126.09M | 182.37M | 187.28M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | -1.23M | -4.07M | 0 | 0 | 0 | 0 | -25.95M | 0 | 0 | 0 |
Operating Income | -25.52M▲ 0% | -26.37M▼ 3.3% | -49.19M▼ 86.5% | -136.01M▼ 176.5% | -267.05M▼ 96.4% | -341.38M▼ 27.8% | -277.32M▲ 18.8% | -186.85M▲ 32.6% | -234.39M▼ 25.4% | -235.09M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -48.8% | -3.34% | -86.51% | -176.49% | -96.35% | -27.83% | 18.76% | 32.62% | -25.44% | - |
EBITDA | -24.97M | -25.88M | -48.28M | -131.8M | -258.34M | -330.38M | -251.37M | -160.14M | -234.39M | -209.16M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -47.82% | -3.65% | -86.52% | -172.99% | -96.01% | -27.88% | 23.91% | 36.29% | -46.36% | -20.85% |
D&A (Non-Cash Add-back) | 549K | 490K | 911K | 4.21M | 8.71M | 11M | 25.95M | 26.71M | 0 | 25.93M |
EBIT | -26.75M | -35.92M | -47.36M | -133.07M | -266.97M | -333.81M | -260.48M | -176.21M | -234.39M | -230.67M |
Net Interest Income | 0 | 0 | 1.56M | 2.88M | 276K | 7.05M | 16.72M | 11.15M | 4.52M | 4.56M |
Interest Income | 0 | 0 | 1.57M | 2.9M | 298K | 7.07M | 16.73M | 11.15M | 4.52M | 4.56M |
Interest Expense | 1.19M | 5.52M | 8K | 25K | 22K | 18K | 13K | 0 | 0 | 0 |
Other Income/Expense | -2.42M | -15.07M | 1.82M | 2.91M | 61K | 7.56M | 16.83M | 10.64M | 4.42M | 4.43M |
Pretax Income | -27.94M▲ 0% | -41.44M▼ 48.3% | -47.37M▼ 14.3% | -133.1M▼ 181.0% | -266.99M▼ 100.6% | -333.82M▼ 25.0% | -260.49M▲ 22.0% | -176.21M▲ 32.4% | -229.97M▼ 30.5% | -230.66M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | -45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.16% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -27.94M▲ 0% | -41.44M▼ 48.3% | -47.37M▼ 14.3% | -133.1M▼ 181.0% | -266.99M▼ 100.6% | -333.82M▼ 25.0% | -260.49M▲ 22.0% | -176.21M▲ 32.4% | -229.97M▼ 30.5% | -230.66M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -63.06% | -48.35% | -14.29% | -181% | -100.6% | -25.03% | 21.97% | 32.36% | -30.51% | -21% |
Net Income (Continuing) | -27.94M | -41.44M | -47.37M | -133.1M | -266.99M | -333.82M | -260.49M | -176.21M | -229.97M | -230.66M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.05▲ 0% | -1.16▼ 10.5% | -1.23▼ 6.0% | -2.91▼ 136.6% | -5.16▼ 77.3% | -6.39▼ 23.8% | -4.97▲ 22.2% | -3.35▲ 32.6% | -4.32▼ 29.0% | -3.73▲ 0% |
EPS Growth % | 54.35% | -10.48% | -6.03% | -136.59% | -77.32% | -23.84% | 22.22% | 32.6% | -28.96% | -14.88% |
EPS (Basic) | -1.05 | -1.16 | -1.23 | -2.91 | -5.16 | -6.39 | -4.97 | -3.35 | -4.32 | - |
Diluted Shares Outstanding | 26.56M | 35.87M | 37.85M | 45.74M | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M | 61.86M |
Basic Shares Outstanding | 26.56M | 35.87M | 37.85M | 45.74M | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M | 61.86M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KOD Balance Sheet
Kodiak Sciences Inc. (KOD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.59M | 90.45M | 339.23M | 972M | 734.81M | 486M | 289.31M | 171.94M | 214.82M | 175.26M |
Cash & Short-Term Investments | 1.4M | 88.25M | 336.48M | 968.97M | 731.51M | 478.93M | 285.51M | 168.07M | 209.86M | 169.53M |
Cash Only | 1.4M | 88.25M | 211.8M | 944.4M | 731.51M | 190.43M | 285.51M | 168.07M | 209.86M | 169.53M |
Short-Term Investments | 0 | 0 | 124.68M | 24.58M | 0 | 288.5M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 2.19M | 2.75M | 0 | 3.3M | 7.07M | 3.8M | 3.86M | 4.95M | 5.73M |
Total Non-Current Assets | 1.65M | 1.74M | 19.64M | 95.34M | 169.41M | 180.62M | 190.06M | 163.64M | 136.72M | 130.75M |
Property, Plant & Equipment | 1.51M | 1.1M | 2.79M | 78.81M | 108.07M | 115.75M | 175.02M | 148.73M | 121.86M | 115.89M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 140K | 140K | 11.84M | 0 | 6.32M | 6.32M | 6.32M | 6.18M | 0 | 6.18M |
Other Non-Current Assets | 0 | 503K | 5.01M | 16.53M | 55.01M | 58.55M | 8.72M | 8.73M | 14.85M | 14.86M |
Total Assets | 3.24M▲ 0% | 92.19M▲ 2741.8% | 358.87M▲ 289.3% | 1.07B▲ 197.4% | 904.22M▼ 15.3% | 666.63M▼ 26.3% | 479.37M▼ 28.1% | 335.58M▼ 30.0% | 351.53M▲ 4.8% | 306.01M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -73.22% | 2741.83% | 289.27% | 197.42% | -15.28% | -26.28% | -28.09% | -30% | 4.75% | -70.08% |
Total Current Liabilities | 9.16M | 4.83M | 11.71M | 31.42M | 64.68M | 52.5M | 41.73M | 25.57M | 45.53M | 49.57M |
Accounts Payable | 3.36M | 1.05M | 2.62M | 8.65M | 12.43M | 9.13M | 13.61M | 3.92M | 12.86M | 11.34M |
Days Payables Outstanding | 2.23K | 782.14 | 1.05K | 749.95 | 520.87 | 302.92 | 191.43 | 53.51 | - | - |
Short-Term Debt | 0 | 0 | 434K | 0 | 3.93M | 9.93M | 9.77M | 0 | 12.06M | 11.66M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -108K | 0 | 5.55M | 0 | 42.13M | 27.41M | 12.27M | 0 | 20.61M | 26.57M |
Current Ratio | 0.17x | 18.74x | 28.97x | 30.93x | 11.36x | 9.26x | 6.93x | 6.72x | 4.72x | 3.54x |
Quick Ratio | 0.17x | 18.74x | 28.97x | 30.93x | 11.36x | 9.26x | 6.93x | 6.72x | 4.72x | 3.54x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 62.82M | 530K | 1.8M | 175.17M | 176.22M | 177.97M | 171.86M | 159.72M | 148.62M | 144.33M |
Long-Term Debt | 9.97M | 0 | 0 | 0 | 99.94M | 100M | 100M | 0 | 47.12M | 44.33M |
Capital Lease Obligations | 0 | 0 | 1.5M | 75.03M | 76.06M | 77.81M | 71.86M | 59.72M | 0 | 104.37M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 52.85M | 530K | 295K | 100.15M | 211K | 162K | 0 | 100M | 101.5M | 100M |
Total Liabilities | 71.98M | 5.36M | 13.51M | 206.6M | 240.9M | 230.46M | 213.59M | 185.29M | 194.15M | 193.91M |
Total Debt | 10.08M | 0 | 1.94M | 77.4M | 179.94M | 187.73M | 181.63M | 70.34M | 59.18M | 55.99M |
Net Debt | 8.69M | -88.25M | -209.86M | -866.99M | -551.57M | -2.7M | -103.88M | -97.73M | -150.68M | -113.54M |
Debt / Equity | - | - | 0.01x | 0.09x | 0.27x | 0.43x | 0.68x | 0.47x | 0.38x | 0.50x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.27x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.54x |
Interest Coverage | -22.57x | -6.51x | -5919.63x | -5322.84x | -12134.91x | -18544.72x | -20036.77x | - | - | - |
Total Equity | -68.74M▲ 0% | 86.83M▲ 226.3% | 345.36M▲ 297.7% | 860.75M▲ 149.2% | 663.32M▼ 22.9% | 436.17M▼ 34.2% | 265.78M▼ 39.1% | 150.29M▼ 43.5% | 157.38M▲ 4.7% | 112.1M▲ 0% |
Equity Growth % | -67.31% | 226.32% | 297.73% | 149.23% | -22.94% | -34.24% | -39.06% | -43.45% | 4.72% | -146.74% |
Book Value per Share | -2.59 | 2.42 | 9.12 | 18.82 | 12.81 | 8.35 | 5.07 | 2.86 | 2.96 | 1.81 |
Total Shareholders' Equity | -68.74M | 86.83M | 345.36M | 860.75M | 663.32M | 436.17M | 265.78M | 150.29M | 157.38M | 112.1M |
Common Stock | 1K | 4K | 5K | 5K | 5K | 5K | 5K | 5K | 6K | 6K |
Retained Earnings | -69.32M | -110.77M | -158.13M | -291.23M | -558.22M | -892.04M | -1.15B | -1.33B | -1.56B | -1.62B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 10K | 53K | 0 | -1.31M | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KOD Cash Flow Statement
Kodiak Sciences Inc. (KOD) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -17.66M | -29.03M | -39.15M | -83.43M | -182.27M | -206.46M | -154.18M | -117.32M | -136.01M | -146.94M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -10.02% | -64.44% | -34.84% | -113.12% | -118.48% | -13.27% | 25.32% | 23.91% | -15.93% | -154.84% |
Net Income | -27.94M | -41.44M | -47.37M | -133.1M | -266.99M | -333.82M | -260.49M | -176.21M | -229.97M | -230.66M |
Depreciation & Amortization | 549K | 490K | 911K | 4.21M | 8.71M | 11M | 25.95M | 26.71M | 18.33M | 17.94M |
Stock-Based Compensation | 275K | 2.67M | 6.11M | 30.67M | 61.38M | 106.03M | 88.56M | 60.21M | 58.86M | 55.13M |
Deferred Taxes | 1.26M | 10.17M | 0 | -51K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.16M | 5.48M | -241K | 49K | 198K | -1.63M | -840K | 355K | 9.92M | 8M |
Working Capital Changes | 7.04M | -6.39M | 1.44M | 14.79M | 14.43M | 11.96M | -7.36M | -28.39M | 6.85M | 2.65M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 2.28M | -2.32M | 1.57M | 5.22M | -2.09M | 1.66M | 5.6M | -9.69M | 8.07M | 4.73M |
Cash from Investing | -209K | -581K | -137M | 104.83M | -38.8M | -336.51M | 249.23M | -755K | -506K | -1.18M |
Capital Expenditures | -209K | -581K | -437K | -7M | -63.3M | -47.36M | -41.43M | -400K | -506K | -1.18M |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 136.56K | 3.18M | 0 | 0 | -290.65K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -503K | -136.56K | -3.18M | 0 | 616K | 290.65K | 0 | 0 | 0 |
Cash from Financing | 9.64M | 116.47M | 299.69M | 717.38M | 8.18M | 1.9M | 31K | 501K | 178.3M | 178.8M |
Debt Issued (Net) | 9.9M | 32.89M | -48K | -5K | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 83.75M | 297.48M | 611.53M | 0 | 1.94M | 242K | 501K | 178.3M | 178.8M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -132K | -487K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -266K | -176K | 2.25M | 105.85M | 8.18M | -49K | -211K | 0 | 0 | 0 |
Net Change in Cash | -8.23M▲ 0% | 86.86M▲ 1155.8% | 123.54M▲ 42.2% | 738.78M▲ 498.0% | -212.89M▼ 128.8% | -541.08M▼ 154.2% | 95.07M▲ 117.6% | -117.57M▼ 223.7% | 41.79M▲ 135.5% | 30.68M▲ 0% |
Free Cash Flow | -17.86M▲ 0% | -29.61M▼ 65.8% | -39.58M▼ 33.7% | -90.43M▼ 128.4% | -245.57M▼ 171.6% | -253.82M▼ 3.4% | -195.61M▲ 22.9% | -117.72M▲ 39.8% | -136.51M▼ 16.0% | -148.12M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -6.22% | -65.76% | -33.67% | -128.45% | -171.57% | -3.36% | 22.93% | 39.82% | -15.97% | -37.86% |
FCF per Share | -0.67 | -0.83 | -1.05 | -1.98 | -4.74 | -4.86 | -3.73 | -2.24 | -2.57 | -2.39 |
FCF Conversion (FCF/Net Income) | 0.63x | 0.70x | 0.83x | 0.63x | 0.68x | 0.62x | 0.59x | 0.67x | 0.59x | 0.64x |
Interest Paid | 0 | 0 | 0 | 0 | 22K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KOD Key Ratios
Kodiak Sciences Inc. (KOD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -458.06% | -21.92% | -22.07% | -35.04% | -60.72% | -74.22% | -84.7% | -149.49% | -253.85% |
Return on Invested Capital (ROIC) | - | - | -55.03% | -157.84% | -379.67% | -93.92% | -69.87% | -130.69% | -593.29% | -1397.8% |
Debt / Equity | - | - | 0.01x | 0.09x | 0.27x | 0.43x | 0.68x | 0.47x | 0.38x | 0.50x |
Interest Coverage | -22.57x | -6.51x | -5919.63x | -5322.84x | -12134.91x | -18544.72x | -20036.77x | - | - | - |
FCF Conversion | 0.63x | 0.70x | 0.83x | 0.63x | 0.68x | 0.62x | 0.59x | 0.67x | 0.59x | 0.64x |
Related:KOD Dividend History·KOD Revenue History·KOD Price History·KOD P/E History·KOD Financial Ratios·KOD Institutional Holders
KOD SEC Filings & Documents
Kodiak Sciences Inc. (KOD) SEC filings — annual & quarterly reports (10-K, 10-Q)
KOD Frequently Asked Questions
Kodiak Sciences Inc. (KOD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kodiak Sciences Inc. (KOD) grew revenue by 0.0% over the past year. Growth has been modest.
Kodiak Sciences Inc. (KOD) reported a net loss of $230.7M for fiscal year 2025.
Dividend & Returns
Kodiak Sciences Inc. (KOD) has a return on equity (ROE) of -149.5%. Negative ROE indicates the company is unprofitable.
Kodiak Sciences Inc. (KOD) had negative free cash flow of $148.1M in fiscal year 2025, likely due to heavy capital investments.